How We Treat lung Cancer during SARS-Cov-2 (COVID-19) Pandemic in India?

Bivas Biswas; Sandip Ganguly; Deepak Dabkara; Joydeep Ghosh; Priyanka Srivastava; Prashant Mehta; Amol Patel; Sainath Bhethanabhotla; Atul Batra; Raja Pramanik; Vineet Govinda Gupta; Chandan Krushna Das; Shubh Mahindru

doi:10.4103/ijmpo.ijmpo_122_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 149-152
DOI: 10.4103/ijmpo.ijmpo_122_20

How I Treat

How We Treat lung Cancer during SARS-Cov-2 (COVID-19) Pandemic in India?

Bivas Biswas

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Sandip Ganguly

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Deepak Dabkara

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Joydeep Ghosh

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Priyanka Srivastava

M.S. Patel Cancer Center, Shreekrishna Hospital and Research Center, Karamsad, Gujarat

,

Prashant Mehta

Department of Medical Oncology/Hematoncology and BMT, Asian Institute of Medical Sciences, Faridabad, Haryana

,

Amol Patel

Department of Medical Oncology, Army Hospital Research and Referral, New Delhi

,

Sainath Bhethanabhotla

Department of Medical Oncology, Care Cancer Institute, Hyderabad, Telangana

,

Atul Batra

Department of Medical Oncology, Care Hospitals, All India Institute of Medical Sciences, New Delhi

,

Raja Pramanik

Department of Medical Oncology, Care Hospitals, All India Institute of Medical Sciences, New Delhi

,

Vineet Govinda Gupta

Department of Medical Oncology, Artemis Hospital, Gurgaon, Haryana

,

Chandan Krushna Das

Regional Cancer Center, Post Graduate Institute of Medical Education and Research, Chandigarh

,

Shubh Mahindru

Department of Surgical Oncology, Ivy Hospital, SAS Nagar, Punjab

› Author Affiliations

Abstract

Full Text

References

References
1 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. Mar 23. doi: 10.1001/jama.2020.4683. Online ahead of print.
2 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21: e181
3 http://cancerindia.org.in/globocan-2018-india-factsheet/ Globocan 2018: India Factsheet. India against Cancer; 2018. Available from: [Last accessed on 2020 Apr 01].
4 Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020 Mar 25;e200980. doi: 10.1001/jamaoncol.2020.0980. Online ahead of print.
5 Tang W, Li X, Xie X, Sun X, Liu J, Zhang J. et al. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2019; 136: 6-14
6 Curran Jr. WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S. et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-60
7 Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A. et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 2020; 38: 124-36
8 Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019; 20: 625-35
9 Patel A, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M. et al. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. Curr Probl Cancer 2020 Mar 17;100571. doi: 10.1016/j.currproblcancer.2020.100571.
10 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33
11 Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92
12 Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393: 1819-30
13 Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040-51
14 Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-9
15 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28;NEJMoa2002032. doi: 10.1056/NEJMoa2002032. Online ahead of print.